Radiometer has added assays for NT-proBNP and Troponin T to the panel of cardiovascular markers that can be assessed at the point of care using its AQT90 Flex Poc immunoassay platform.
This follows the company being granted non-exclusive license under patent rights of Roche Diagnostics.
The addition of NT-proBNP and Troponin T extends a portfolio of tests that already includes Troponin I, CKMB and Myoglobin and allows users to select the markers they need for the rapid diagnosis of congestive heart failure (CHF) and acute myocardial infarction (AMI).
The breadth of this panel also means that the AQT90 Flex can help with risk stratification in patients with CHF and AMI, for the selection of more intensive therapy and interventions in patients with elevated marker levels.
Designed to take up minimum bench space, the AQT90 Flex provides laboratory standard results at the point of care.
Up to 30 blood samples can be analysed per hour, and all the usual steps required for this type of testing have either been completely removed or automated.
This reduces the risk of errors and cuts the costs associated with resampling.
As the AQT90 Flex is a closed system, the risk of operator contact with blood and waste has been eliminated.
In addition to measuring cardiovascular markers, the AQT90 Flex can also be used to monitor infection, coagulation and pregnancy markers using a single whole blood sample.
